TroFuse-015 (NCT06356311) is Merck’s Phase 3 trial of sacituzumab tirumotecan (sac-TMT), an investigational TROP2-directed antibody-drug conjugate licensed from Kelun-Biotech, versus physician’s choice chemotherapy in 473 patients with third-line or later gastroesophageal adenocarcinoma. On November 20, 2026, Merck reported the primary overall survival endpoint was met; PFS by central review was not. No hazard ratio has been released.
See the KOL ReactionGlobal, randomized, open-label Phase 3. 473 patients with locally advanced unresectable or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma after at least two prior lines of therapy. Sac-TMT vs treatment of physician’s choice (trifluridine-tipiracil, irinotecan, paclitaxel or docetaxel). Enrollment regardless of HER2 status; TROP2 tested centrally for stratification. ClinicalTrials.gov NCT06356311
✅ Overall survival (primary) met at the final analysis: statistically significant and clinically meaningful improvement vs physician’s choice, generally consistent regardless of TROP2 expression. ❌ PFS by blinded independent central review (secondary) not met. Objective response rate nominally favored sac-TMT but was not formally tested. No hazard ratio, medians or p-values have been released. Source: Merck press release, Nov 20, 2026
Merck reported the safety profile was consistent with previous studies of sac-TMT, with no new safety signals. No adverse-event rates have been released. Source: Merck press release
⚠ Investigational. Sac-TMT is not approved by the FDA in any indication and is not approved for gastroesophageal cancer anywhere. It is approved in China in other indications (Kelun-Biotech). Merck plans to discuss the data with regulators and present them at an upcoming medical meeting. Sac-TMT is a different drug from sacituzumab govitecan (Trodelvy).
Create a free account, pick the tumor types you cover, and go beyond the tweet — the intelligence pharma teams use to map influence and prepare for engagement:
𝕏Phase 3 TROFUSE-015: Sac-TMT, a TROP2-directed ADC, improved OS in 3L+ gastroesophageal adenocarcinoma, but did not meet PFS. Looking forward to the full data presentation and further discussion! https://t.co/5KXIxqUBjf
𝕏Interesting to see yet another ADC improving OS, but not PFS, in gastric cancer. Certainly preferable to the opposite scenario, which we see all too often. https://t.co/FEhyniRkI5
𝕏👁️ TroFuse-015 Phase 3 (Merck press release) 🎯 Gastroesophageal adenocarcinoma after 2 or more prior lines 👥 473 patients randomised 💊 Sacituzumab tirumotecan (TROP2 ADC) vs physician's choice: trifluridine-tipiracil, irinotecan, paclitaxel or docetaxel ✅ OS primary endpoint met at final analysis ❌ PFS by central review not met ⚠️ No HR or medians released yet A third-line gastroesophageal trial that wins on overall survival deserves attention. But... 1st - What is the size of the OS benefit? 2nd - how an OS win sits with a PFS miss (which can point to post-progression effects or crossover rather than tumour control). 3rd- The benefit being independent of TROP2 expression would also mean no biomarker test before treatment. So many ADCs these days... Do not confuse sac-TMT with sacituzumab govitecan: different payload, different linker. Also, Izalontamab brengitecan (PANKU Esophagus01) was for 2nd line ESCC. #GIOnc #GastricCancer #ADC #TROP2 https://t.co/rBERYEISVq
𝕏@KoheiShitara On the heels of the sone-ve data also showing an OS but not a PFS benefit in refractory gastric ca. Looking forward to seeing the data soon!
𝕏Sacituzumab Tirumotecan Improves OS in 3L+ Gastroesophageal Cancer https://t.co/ct5ii0arMQ
𝕏🎯 Another phase III OS win for ADCs! TroFuse-015 (n=473): TROP2 ADC sacituzumab tirumotecan improves OS vs physician’s choice in ≥3L gastroesophageal cancer. But PFS endpoint missed. No HRs or medians disclosed yet. Intriguing OS–PFS discordance! Full data needed. https://t.co/QWq6tceZAy @OncoAlert @weoncologists @urotoday @Uromigos @OncoAlert and Faculty: @DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot @Markuseckstein3
Randomized, open-label, multicenter global Phase 3 (outcomes assessor masked). Actual enrollment 473. Randomization stratified by TROP2 expression, geographic region and ECOG performance status (OncLive, CancerNetwork).
Advanced unresectable or metastatic gastric, GEJ or esophageal adenocarcinoma after ≥2 prior chemotherapy and/or immunotherapy regimens; any HER2 status (HER2+ must have had trastuzumab where available); ECOG 0–1; tissue for central TROP2 testing. Prior lines included a fluoropyrimidine and a platinum doublet (OncLive).
Sac-TMT 4 mg/kg IV on days 1, 15 and 29 of each 42-day cycle.
Physician’s choice: trifluridine-tipiracil, irinotecan, paclitaxel or docetaxel.
Primary: overall survival. Secondary: PFS (BICR), objective response rate, duration of response, safety.
Merck Sharp & Dohme LLC. Sac-TMT licensed from Kelun-Biotech (Merck holds rights outside Greater China).
At the final analysis, sac-TMT showed a statistically significant and clinically meaningful improvement in OS vs physician’s choice; results were generally consistent across subgroups regardless of TROP2 expression. Merck has not disclosed the hazard ratio, confidence interval, p-value or median OS.
OS met · magnitude not yet disclosedPFS by blinded independent central review did not meet its endpoint. ORR nominally favored sac-TMT but was not formally tested under the prespecified analysis plan. No PFS or ORR figures have been released.
Source: Merck press release, Nov 20, 2026Consistent with previous studies of sac-TMT; no new safety signals (Merck). Rates not yet disclosed.
Source: Merck press release⚠ Investigational: sac-TMT has no FDA approval in any indication. TroFuse-015 is the second positive Phase 3 readout for sac-TMT in Merck’s TroFuse program, after TroFuse-005 in endometrial cancer. Physicians are waiting for the size of the OS benefit and an explanation of the OS–PFS discordance before judging its place in third-line gastroesophageal cancer.
Source: Merck press release
𝕏Merck's ADC sac-TMT scored another Phase 3 win, this time in gastric cancer, as it looks to offset Keytruda's looming patent cliff. https://t.co/7b4XoZYdA5
𝕏🚨Positive Phase III trial in #GastricCancer 💊TroFuse015: sacituzumab tirumotecan (TROP2 ADC) 📊Significant OS benefit in 3L+ gastroesophageal cancer (n=473) ⚠️PFS not met but first TROP2 ADC with OS benefit @KoheiShitara @YJanjigianMD @KlempnerSam https://t.co/JuMySXDGEi
𝕏A TROP2-directed ADC improved OS in 3L+ gastroesophageal adenocarcinoma. 💊📈 The phase 3 TroFuse-015 trial met its primary OS end point with sac-TMT vs treatment of physician’s choice, but missed its PFS end point. Here’s what we know 👇 https://t.co/rCOAuhrdyN #esocsm #oncology
𝕏🧬 Phase 3 TroFuse-015 results in advanced gastroesophageal cancer: ✅ Sacituzumab tirumotecan improved overall survival vs. chemotherapy. ❌ The PFS endpoint was not met. Detailed data are awaited. 🔗 https://t.co/isYCllo61A https://t.co/qXnwwDp3O6
TroFuse-015 (NCT06356311, MK-2870-015) is a global, randomized, open-label Phase 3 trial sponsored by Merck (MSD) that compared sacituzumab tirumotecan (sac-TMT), a TROP2-directed antibody-drug conjugate, with treatment of physician's choice in 473 patients with locally advanced unresectable or metastatic gastroesophageal adenocarcinoma (gastric, gastroesophageal junction or esophageal) who had received at least two prior lines of therapy.
Merck announced on November 20, 2026 that TroFuse-015 met its primary endpoint of overall survival at the final analysis, with a statistically significant and clinically meaningful improvement versus treatment of physician's choice, generally consistent across subgroups regardless of TROP2 expression. The secondary endpoint of progression-free survival by blinded independent central review was not met. Objective response rate nominally favored sac-TMT but was not formally tested. Merck has not released a hazard ratio, medians or p-values; full data will be presented at an upcoming medical meeting.
Treatment of physician's choice: trifluridine-tipiracil, irinotecan, paclitaxel or docetaxel. Sac-TMT was given at 4 mg/kg intravenously on days 1, 15 and 29 of each 42-day cycle (ClinicalTrials.gov NCT06356311).
No. Sacituzumab tirumotecan is investigational in the United States and has no FDA approval in any indication, including gastroesophageal cancer. It is approved in China in other indications, where it was developed by Kelun-Biotech, which licensed it to Merck outside Greater China. Merck said it will discuss the TroFuse-015 data with regulatory authorities.
No. Both target TROP2 with the same sacituzumab antibody, but they are different drugs: sacituzumab tirumotecan (sac-TMT, MK-2870) carries a belotecan-derived topoisomerase I inhibitor payload (KL610023) attached with different conjugation chemistry, while sacituzumab govitecan (Trodelvy) carries SN-38.